Despite dyslipidaemia management guidelines, many patients
do not reach low-density lipoprotein cholesterol targets due to insufficiently
intensive regimens or lack of adherence to their medication. This was a retrospective cohort study on the Pharmacoepidemiologic General Research
eXtension (PGRx)-acute coronary syndrome (ACS) registry. Patients
included were
Cite this article
97
Downloads
2
Citations
413
Views
Announcements
Open Access
Original Research
Patient characteristics, treatment patterns, and adherence to lipid-lowering therapies following an acute coronary syndrome
Eric Bruckert1, Gaelle Desamericq2, Artak Khachatryan3, Patrick Ngo4, Gaelle Gusto5, Francesc Sorio-Vilela6,*
Show Less
1
Endocrinologie, Hospital Pitie-Salpetriere, 75013, Paris, France
2
Health Economics, Amgen SAS, 92100, Boulogne-Billancourt, France
3
Pharmacoepidemiology, Certara, Evidence & Access (previously - Analytica Laser), EC1N 6SN, London, United Kingdom
4
Medical Affairs, Amgen SAS, 92100, Boulogne-Billancourt, France
5
Real World Evidence, Certara, Evidence & Access (previously - Analytica Laser), 75009, Paris, France
6
Health Economics and Outcomes Research, Amgen GmbH, 6343, Rotkreuz, Switzerland
*Correspondence: fsorio@amgen.com (Francesc Sorio-Vilela)
Rev. Cardiovasc. Med. 2020, 21(4), 643–650;
https://doi.org/10.31083/j.rcm.2020.04.189
Submitted: 16 September 2020 | Revised: 9 November 2020 | Accepted: 10 November 2020 | Published: 30 December 2020
Copyright: © 2020 Bruckert et al. Published by IMR Press.
This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
Abstract
Keywords
Acute coronary syndrome
dyslipidaemias
treatment intensity
adherence
lipid lowering therapy
Figures
Fig. 1.